What is Argireline used for in the supplied evidence?

Argireline is a cosmetic name for acetyl hexapeptide-8, also listed as acetyl hexapeptide-3. The supplied evidence describes it as a topical anti-aging peptide studied for expression-line and wrinkle-related cosmetic uses, with mixed human evidence.

How is Argireline proposed to work?

The proposed pathway involves SNAP-25 and the SNARE complex, which participate in acetylcholine release at nerve endings. Source material reports cell-system inhibition of neurotransmitter release, but also notes uncertainty about whether topical application reaches the relevant depth in living facial tissue.

Is Argireline FDA approved?

No. The supplied profile states that Argireline is not FDA approved and classifies its current status as cosmetic use.

What side effects are reported?

Reported tolerability signals are mild in the supplied source: rare skin irritation, rare redness or tingling, and no serious adverse effects reported in the summarized research discussion. Individual reactions can vary.

What dosing information is available?

The source gives limited community dose information and a research formulation concentration of 5-10% for topical products. It also lists topical serums or creams and ongoing use for maintained effects.

Skin & Hair Research - early research

Argireline

Also known as: Acetyl Hexapeptide-3, Acetyl Hexapeptide-8

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

Topical cosmetic peptide researched for expression-line and wrinkle appearance.

Status

Research

Evidence level: early research

Typical dose

Limited community data available

Topical

Researched for

Wrinkle reduction, forehead lines, eye area anti-aging

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

Preclinical - Limited evidence and no established human dosing

Use the tools

In plain language

Synthetic cosmetic also known as acetyl hexapeptide-8 and acetyl hexapeptide-3.
Studied for wrinkle reduction, forehead lines, and eye-area anti-aging.
Listed status: cosmetic use, widely available; not FDA approved.
Evidence level in the source is Limited Research, with mixed human findings.
Topical use is described for serums and creams; community dose detail is limited.

How it's thought to work

Argireline is described as an acetyl hexapeptide-8 fragment connected to SNAP-25, a protein involved in the SNARE machinery for acetylcholine release. The source reports that early laboratory work found neurotransmitter-release inhibition in cell systems. A key limitation is topical delivery: the supplied review summary notes disagreement about skin penetration and states that demonstration of the marketed muscle-inhibition mechanism was not shown.

What the research shows

Where the research stands

The source summary cites a 2002 Blanes-Mira study using a 10% oil-in-water emulsion and reporting a 30% wrinkle-depth reduction, alongside cell-assay support for SNARE interference. It also describes a small double-blind split-face study in 19 women where four weeks of Argireline serum did not significantly outperform placebo by VISIA imaging and was not considered a botulinum toxin substitute. A 2025 review is reported to have found inconsistent penetration estimates, about 30% stratum-corneum passage in one study versus about 0.2% in another, and no proof of the proposed muscle-inhibition mechanism. Overall, the supplied evidence frames Argireline as a plausible cosmetic peptide with limited and mixed human data, while noting no serious adverse effects reported.

What it shows

✓ Early research

Limited evidence and no established human dosing

△ Limitations

Early research findings may not translate directly to human outcomes.

Bottom line: Cosmetic use - widely available Not FDA approved

Typical dosing

CommunityCommunity dataset

Limited community data available

See research protocols

Range: See research dosing

Community row reports limited dose detail and points to research dosing/protocols; this is not medical advice.

Research dosing

Early researchEarly research - limited data

Doses observed in studies

5-10% concentration in formulations

Research Literature - Observed in studies

Early research findings may not translate directly to human outcomes.

Duration: Ongoing use for maintained effects
Administration: Topical (serums, creams)

Timing & administration

Best time to take

Morning and evening (topical)

Twice daily topically

Food recommendation

With or without food

Why this timing?

The source links twice-daily topical use with maintaining cosmetic effects, while broader efficacy evidence remains limited and mixed.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Generally very safe
Mild skin irritation
Redness or tingling
Fewer side effects than botulinum toxin

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

Sequence

Ac-EEMQRR-NH2

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Argireline

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Argireline

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions